The global tigecycline market is expected to grow at a significant CAGR of 12.7% during the forecast period (2022-2028). Tigecycline is a glycylcycline that acts as a protein synthesis inhibitor with a broad scope. Tigecycline has a bacteriostatic effect because it binds to the 30S ribosomal subunit of bacteria, which prevents aminoacyl-tRNA from interacting with the A site of the ribosome. Tigecycline has also been demonstrated to have a bactericidal effect against L. pneumophila and S. pneumonia isolates. Tigecycline is an antibiotic that is used to treat a variety of bacterial illnesses. Tigecycline is a first-generation glycylcycline that is given intravenously. The rise in antibiotic resistance in microorganisms such as Acinetobacter baumannii, Staphylococcus aureus, and E. coli was the catalyst for the discovery of Tigecycline.
A full report of Global Tigecycline Market is available at:https://orionmarketreports.com/global-tigecycline-market-2/94645/
Tigecycline is a tetracycline derivative antibiotic that has been structurally modified to expand its therapeutic action to Gram-negative and Gram-positive bacteria, including multidrug-resistant pathogens. During the forecast period, rising demand for tigecycline as an antibiotic is expected to drive market growth. The European Society of Clinical Microbiology and Infection recommends tigecycline as a possible salvage therapy for difficult and severe refractory Clostridium difficile infections.
Tigecycline is also used in the treatment of immune-compromised patients and cancer patients. Thus, the rising prevalence of cancer is one factor propelling the growth of the market. For instance, according to the Globocan 2020 report, there were 19,292,789 new cancer cases reported worldwide, with 9,958,133 cancer-related mortalities. Furthermore, tigecycline has the potential to be used in the treatment of acute myeloid leukemia. Tigecycline is given as a gradual intravenous infusion every 12 hours. Patients with compromised liver function are provided tigecycline at a lower dose.
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
- By Target Bacteria Type
- By Application
- By Distribution Channel
- Regions covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Landscape: Pfizer Inc., Abbott Laboratories, Hisun Pharma among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
- Deviation from the pre-COVID-19 forecast
- Most affected region and segment
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Tigecycline Market – Segmentation
By Target Bacteria Type
- Gram-Positive Bacteria
- Gram-Negative Bacteria.
By Application
- Skin & Soft-tissue Infection
- Complicated Intra-abdominal Infections
- Community-acquired Bacterial Pneumonia
By Distribution Channel
- Online
- Offline
About Us:
Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
